Diagnosis of PCNSL can be challenging, but genomic cfDNA testing on CSF has emerged as a new tool. The disease is now often curable in patients younger than 65 years, with several promising clinical trials ongoing for older patients.
Patients with low-risk differentiated thyroid cancer can omit radioactive iodine after total thyroidectomy without increasing their risk for functional, structural, or biologic events.
A consensus statement presenting biomarker testing algorithms for the management of patients with thyroid cancer. The algorithms balance aspirational care with what is practical and feasible.
An unusual co-occurrence of a solitary fibrous tumor of the thyroid and papillary thyroid carcinoma in a woman with no prior medical history who presented with a year-long indwelling cervical swelling.
Cigarette smoking is known to promote tumor metastasis, but do e-cigarettes also have an impact? This mini review synthesizes the current literature on the topic and discusses potential public health implications.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.
Please note, this webinar is not intended for healthcare professionals based in the US and UK.
An unusual co-occurrence of a solitary fibrous tumor of the thyroid and papillary thyroid carcinoma in a woman with no prior medical history who presented with a year-long indwelling cervical swelling.
Fatal outcomes in three cases, despite aggressive treatment, emphasize the poor prognosis of fulminant myocarditis related to immune checkpoint inhibitor therapy.
A patient treated with carboplatin for stage I seminoma developed hematuria and acute kidney injury. It is crucial to recognize this rare but serious complication and start treatment promptly to prevent further kidney damage.
How do nutrition, supplements and antibiotics impact patient outcomes?
Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.
Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.
Breast cancer (BC) is the most common cancer worldwide and is the leading cause of cancer-related mortality among women, affecting approximately 2.26 million women [ 1 , 2 ]. Early detection and advancements in primary cancer treatment, including …
BRCA1 (Breast Cancer 1) is a tumor suppressor gene with a role in DNA repair by Homologous Recombination (HR), and maintenance of genomic stability that is frequently investigated in breast, prostate, and ovarian cancers. BRCA1 mutations or …
We conducted a systematic review of studies that report use of minimally invasive approaches for management of colorectal cancer in Africa. This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses …
Cardiovascular disease and cancer are the leading causes of death in the Western world. The associated risk factors are increased by smoking, hypertension, diabetes, sedentary lifestyle, aging, unbalanced diet, and alcohol consumption. Therefore …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
A series of patient cases underpin this interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.
An independent symposium at the 10th COMy World Congress focusing on BCMA-targeting strategies for the treatment of multiple myeloma. Gain insights into the latest clinical data and the implications for clinical practice.
The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.
Supported by:
Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Breast cancer (BC) is the most common cancer in women worldwide, with over 2.3 million new cases in 2020 [ 1 ]. Its incidence (in absolute numbers) is rising in low- and middle-income countries (LMIC). Globally, ~ 7.8 million women alive in 2020 …
Chronic breast cancer-related lymphedema (BCRL) affects approximately 20% of breast cancer survivors, manifesting as an accumulation of protein-rich interstitial fluid within the suprafascial tissue of the arm due to compromised lymphatic drainage …
Improved treatments for triple-negative breast cancer (TNBC) are urgently required in the attempt to achieve more favorable prognosis. Immune checkpoint inhibition targeting the PD-1/PD-L1 (Programmed Death-Ligand 1) axis has now become a part of …
The combination therapy of lenvatinib plus pembrolizumab (LP) is increasingly recognized as an important second-line regimen for advanced or recurrent endometrial cancer (EC). However, the safety and efficacy of conversion surgery with low …
Diagnosis of PCNSL can be challenging, but genomic cfDNA testing on CSF has emerged as a new tool. The disease is now often curable in patients younger than 65 years, with several promising clinical trials ongoing for older patients.
Patients with low-risk differentiated thyroid cancer can omit radioactive iodine after total thyroidectomy without increasing their risk for functional, structural, or biologic events.
